Human Rho GDP-dissociation inhibitor 2(ARHGDIB) ELISA kit

Code CSB-EL002038HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Human ARHGDIB ELISA Kit was designed for the quantitative measurement of Human ARHGDIB protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 25 pg/mL-1600 pg/mL and the sensitivity is 6.25 pg/mL.

Target Name Rho GDP dissociation inhibitor (GDI) beta
Alternative Names Arhgdib ELISA Kit; D4 ELISA Kit; D4 GDP dissociation inhibitor ELISA Kit; GDIA 2 ELISA Kit; GDIA2 ELISA Kit; GDID 4 ELISA Kit; GDID4 ELISA Kit; GDIR2_HUMAN ELISA Kit; GDP dissociation inhibitor D4 ELISA Kit; LY GDI ELISA Kit; Ly-GDI ELISA Kit; LYGDI ELISA Kit; MGC108926 ELISA Kit; RAP1GN1 ELISA Kit; Rho GDI 2 ELISA Kit; Rho GDI beta ELISA Kit; Rho GDI2 ELISA Kit; Rho GDP dissociation inhibitor (GDI) beta ELISA Kit; Rho GDP dissociation inhibitor 2 ELISA Kit; Rho GDP dissociation inhibitor beta ELISA Kit; Rho GDP-dissociation inhibitor 2 ELISA Kit; Rho-GDI beta ELISA Kit; RhoGDI2 ELISA Kit
Abbreviation ARHGDIB
Uniprot No. P52566
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 25 pg/mL-1600 pg/mL
Sensitivity 6.25 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Signal Transduction
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human ARHGDIB in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 87
Range % 85-93
1:2 Average % 104
Range % 96-108
1:4 Average % 92
Range % 85-96
1:8 Average % 101
Range % 98-105
The recovery of human ARHGDIB spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 92 88-96
EDTA plasma (n=4) 103 98-107
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1600 2.921 2.844 2.883 2.711
800 2.334 2.241 2.288 2.116
400 1.534 1.491 1.513 1.341
200 0.887 0.867 0.877 0.705
100 0.596 0.581 0.589 0.417
50 0.370 0.362 0.366 0.194
25 0.238 0.234 0.236 0.064
0 0.173 0.171 0.172  
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. Regulates reorganization of the actin cytoskeleton mediated by Rho family members.
Gene References into Functions
  1. RhoGDIbeta overexpression led to downregulation of miR-200c, whereas miR-200c was able directly to target 3'-UTR of jnk2mRNA and attenuated JNK2 protein translation, which resulted in attenuation of Sp1mRNA and protein expression in turn, inhibiting Sp1-dependent MMP-2 transcription. PMID: 28846829
  2. Binders to RhoGDI2 as a potential anti-cancer target have been first reported, and their weak interactions were depicted using NMR spectroscopy. PMID: 27721047
  3. Delta19RhoGDIbeta has an apoptosisindependent role in the phorbol 12myristate 13acetate induced differentiation of THP1 cells to macrophages. PMID: 28260067
  4. The caspase-3-cleaved RhoGDIbeta is a possible determinant to promote cancer spreading. PMID: 26919575
  5. Our interpretation of these contradictions is that truncation and/or mutation of RhoGDI2 perturbs its conformation to expose a site that adventitiously binds FLNA and is not a bona-fide interaction. PMID: 26707877
  6. Results show that RhoGDI2 suppresses bladder cancer metastatic colonization via negative regulation of RhoC activity, providing a rationale for the development of therapeutics that target RhoC signaling. PMID: 25516960
  7. These findings indicate that RhoGDI2 repressed the activity of Rac1 and may be involved in the rearrangement of cytoskeleton in lung cancer cells. PMID: 25562149
  8. Short hairpin RNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9. PMID: 25266803
  9. RhoGDI2 overexpression is associated with tumor growth, metastasis, and chemoresistance in gastric cancer. PMID: 24721928
  10. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. PMID: 24788627
  11. RhoGDI2 inhibits trophoblast cell migration, and this function may involve suppression of RAC1 activation. PMID: 24554735
  12. 14-3-3sigma is a RhoGDI2-regulated gene that appears to be important for suppressing the chemoresistance of gastric cancer cells. PMID: 24185104
  13. These results suggest that RhoGDIbeta has mitotic functions, including regulation of cytokinesis and bipolar spindle formation PMID: 23232495
  14. Rictor regulates cell migration by suppressing RhoGDI2. PMID: 22777355
  15. RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Conventional type PKCalpha is responsible for this phosphorylation. PMID: 22469974
  16. Expression of ARHGDIB variants 6a, 6b, and 6c appears to be restricted to cancer cells and normal placental tissue, suggesting that these variants possess cancer-specific functions. PMID: 23206989
  17. The ARHGDIB is a lymphoid-specific intrinsic negative regulator of HIV-1 replication that acts by simultaneously inhibiting RhoA and Rac1 functions. PMID: 21936715
  18. Results suggest that D4-GDI may function as a biphasic regulator of breast cancer progression and metastasis. PMID: 22674302
  19. We delineate the mechanism by which RhoGDI2 promotes gastric cancer cell invasion and chemoresistance. In total, 47 differential protein spots were identified; 33 were upregulated, and 14 were downregulated by RhoGDI2 overexpression. PMID: 22364609
  20. RhoGDI2 suppresses lung metastasis in mouse models by reducing the expression of isoforms V1 and V3 of the proteoglycan versican. RhoGDI2 suppressed metastasis by altering inflammation in the tumor microenvironment. PMID: 22406535
  21. Overexpression of RhoGDI2 correlates with tumor progression in colorectal carcinoma. PMID: 21861235
  22. activation of the Src family members and downstream signalling proteins are associated with a good prognosis in transitional cell carcinoma of the bladder, and activated Src has a positive relationship with RhoGD12. PMID: 22353809
  23. PLCgamma plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells. PMID: 21986528
  24. identification of LyGDI as a binding partner of SHIP, associating inducibly with the SHIP/Grb2/Shc complex PMID: 21695085
  25. This study has revealed that Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and the HSP70/90 organizing protein have a critical role to play in resistance to cyclin-depedent kinases inhibitor. PMID: 21067243
  26. RhoGDI2 is likely to be involved in lung tumor malignancy and metastasis. PMID: 20596634
  27. High LyGDI serum levels are associated with ovarian cancer. PMID: 20375790
  28. RhoGDI2 is associated with c-Src in bladder tumors, where the expression of both is diminished as a function of stage. c-Src binds to and phosphorylates RhoGDI2 resulting in enhanced metastasis suppressive potency. Review. PMID: 20013033
  29. These data suggest that D4-GDI of Rho family GTPase may be regulated during apoptosis through the caspase-3 mediated cleavage of the GDI protein. PMID: 11989976
  30. Results demonstrate that modification of Rho guanine nucleotide dissociation inhibitor (GDI) 2 during apoptosis is often accompanied by their relocalisation between cellular compartments [Rho GDI 2 ] PMID: 12203895
  31. the interaction of Vav1 and Ly-GDI creates a fine tuning mechanism for the regulation of intracellular signaling pathways leading to NFAT stimulation PMID: 12386169
  32. RhoGDI2 has a role in progression of bladder cancer PMID: 15173088
  33. RhoGDI2 may be implicated in the progress of malignancy. PMID: 17487395
  34. One gene identified by microarray gene expression analysis, RhoGDI2, was tested and confirmed to be metastasis supressor gene; results from cells expressing RhoG-two molecular effectors of RhoGDI2 signaling were identified: endothelin-1 and Neuromedin U. PMID: 17826660
  35. Rho-GDI beta has two roles: one that suppresses tumor progression by inhibiting migration and the other that stimulates it by enhancing Cox-2 expression PMID: 18006811
  36. D4-GDI with two mutations (V68L & V69A) inhibited GDP dissociation from Rho in a dominant negative manner. It accelerates invasion via regulation of cytoskeletal machinery. PMID: 18037226
  37. Transgenic mice with T cell-specific expression display altered cellular immunity against cytozoic pathogens PMID: 18689726
  38. Overexpression of D4-GDI is associated with breast cancer. PMID: 19269969
  39. RhoGDI2 metastasis inhibition works through Rho GTPases but via a mechanism distinct from inhibition of membrane association. PMID: 19276387
  40. phosphorylation by Src enhances RhoGDI2 metastasis suppression and loss of Src relieves metastasis suppression in tumor cells that maintain RhoGDI2 expression. PMID: 19321744
  41. RhoGDI2 is involved in gastric tumor growth and metastasis, and that RhoGDI2 may be a useful marker for tumor progression of human gastric cancer. PMID: 19351766
  42. Results show that the established nerve invasion model and the consensus signature of perineural invasion could be instrumental in the identification of novel therapeutic targets of pancreatic cancer as exemplified by KIF14 and ARHGDIbeta. PMID: 19509238

Show More

Hide All

Subcellular Location Cytoplasm, cytosol.
Protein Families Rho GDI family
Tissue Specificity Detected in bone marrow, thymus and spleen.
Database Links

HGNC: 679

OMIM: 602843

KEGG: hsa:397

STRING: 9606.ENSP00000228945

UniGene: Hs.504877

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1